JPWO2020113182A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020113182A5
JPWO2020113182A5 JP2021530785A JP2021530785A JPWO2020113182A5 JP WO2020113182 A5 JPWO2020113182 A5 JP WO2020113182A5 JP 2021530785 A JP2021530785 A JP 2021530785A JP 2021530785 A JP2021530785 A JP 2021530785A JP WO2020113182 A5 JPWO2020113182 A5 JP WO2020113182A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
group
unsubstituted
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511786A (ja
JP2022511786A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063876 external-priority patent/WO2020113182A1/en
Publication of JP2022511786A publication Critical patent/JP2022511786A/ja
Publication of JP2022511786A5 publication Critical patent/JP2022511786A5/ja
Publication of JPWO2020113182A5 publication Critical patent/JPWO2020113182A5/ja
Pending legal-status Critical Current

Links

JP2021530785A 2018-11-30 2019-11-29 新規芳香族化合物によるナチュラルキラー細胞およびilc3細胞の増殖 Pending JP2022511786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774114P 2018-11-30 2018-11-30
US62/774,114 2018-11-30
PCT/US2019/063876 WO2020113182A1 (en) 2018-11-30 2019-11-29 Expansion of natural killer cells and ilc3 cells with novel aromatic compounds

Publications (3)

Publication Number Publication Date
JP2022511786A JP2022511786A (ja) 2022-02-01
JP2022511786A5 JP2022511786A5 (https=) 2023-08-03
JPWO2020113182A5 true JPWO2020113182A5 (https=) 2023-08-03

Family

ID=69005918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530785A Pending JP2022511786A (ja) 2018-11-30 2019-11-29 新規芳香族化合物によるナチュラルキラー細胞およびilc3細胞の増殖

Country Status (13)

Country Link
US (1) US20230028680A1 (https=)
EP (1) EP3887508A1 (https=)
JP (1) JP2022511786A (https=)
KR (1) KR20210111762A (https=)
CN (1) CN113454207A (https=)
AU (1) AU2019387491A1 (https=)
BR (1) BR112021010245A2 (https=)
CA (1) CA3119427A1 (https=)
EA (1) EA202191508A1 (https=)
MX (1) MX2021006398A (https=)
PH (1) PH12021551241A1 (https=)
SG (1) SG11202105213XA (https=)
WO (1) WO2020113182A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252464A1 (en) * 2019-06-14 2020-12-17 Celularity Inc. Populations of natural killer cells for treating cancers
US20220273716A1 (en) * 2019-07-25 2022-09-01 Celularity Inc. Populations of natural killer cells comprising a cd38 chimeric antigen receptor
WO2021155312A1 (en) * 2020-01-29 2021-08-05 Celularity Inc. Placental derived natural killer cells for treatment of coronavirus infections
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
US20240082398A1 (en) * 2021-01-15 2024-03-14 City Of Hope Methods of preparing and expanding type i innate lymphoid cells and therapeutic uses thereof
WO2023278628A1 (en) * 2021-06-29 2023-01-05 Celularity Inc. Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
AU2023249795A1 (en) 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
ZA200804717B (en) 2005-12-29 2010-02-24 Anthrogenesis Corp Improved composition for collecting and preserving a placental stem cells and methods of using the composition
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
ES2421191T3 (es) * 2006-05-03 2013-08-29 Symrise Ag Antagonistas del receptor de Ah
KR20220122774A (ko) 2007-09-26 2022-09-02 셀룰래리티 인코포레이티드 인간 태반 관류액으로부터의 혈관형성 세포
AU2013203936A1 (en) * 2008-10-30 2013-05-02 Novartis Ag Compounds that expand hematopoietic stem cells
RU2013120966A (ru) * 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
NZ733213A (en) * 2014-12-31 2022-10-28 Celularity Inc Natural killer cells and uses thereof
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
WO2018195397A2 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2023171766A5 (https=)
Candido et al. Cancer-related inflammation
US9925220B2 (en) Method of expanding double negative T cells
US10457683B2 (en) Aryl hydrocarbon receptor antagonists and uses thereof
IL267161A (en) JAK2 and ALK2 inhibitors and their use
US12195475B2 (en) Compounds for the treatment of kinase-dependent disorders
ES2959645T3 (es) Materiales y métodos para el tratamiento del cáncer
He et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
JP2004502691A (ja) 抗癌薬としての置換トリアゾロピリミジン
JP2016522232A5 (https=)
JP2010513523A5 (https=)
JP2014503567A5 (https=)
JPWO2020113182A5 (https=)
US11696928B2 (en) Compounds and use thereof in the expansion of stem cells and/or progenitor cells
RU2674262C2 (ru) Трициклическое соединение и ингибитор jak
CN113454207A (zh) 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
Isvoranu et al. Therapeutic potential of interleukin-21 in cancer
Ou et al. Heterocyclic-modified imidazoquinoline derivatives: Selective TLR7 agonist regulates tumor microenvironment against melanoma
Du et al. The different effects of IFN‐β and IFN‐γ on the tumor‐suppressive activity of human amniotic fluid‐derived mesenchymal stem cells
EP3228701A1 (en) Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
US20240360143A1 (en) [1,2,4]triazolo[4,3-a]pyrimidin-7(8h)-one as mitochondrial pyruvate carrier inhibitors for use in the treatment of cancer
Wang et al. Tumor Microenvironment Onmyoji: Cytokines with Dual Protumor and Antitumor Roles
JP5782426B2 (ja) 制御性樹状細胞の作製方法
US20220251104A1 (en) Aromatic compounds for use in activating hematopoietic stem and progenitor cells
Lee Comparative Analysis of Cytokine Levels in Multiple Myeloma Patients: Implications for Natural Killer Cells and Therapeutic Monoclonal Antibodies